Moderna Stock News

Moderna Inc. NASDAQ: MRNA made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. mRNA vaccines deliver a virus's blueprints or genetic instructions to the cells to trigger the immune system to make antibodies to protect against it.

Ähnlich wie Biontech kämpft auch Moderna darum, in einer Post-COVID-19-Welt zurechtzukommen. Neben Forschungserfolgen braucht es Einsparungen.

Moderna was a huge pandemic name, but has struggled since the earlier days of the health crisis. The company is looking to introduce new products and then lower its R&D budget.

Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.

Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.

Moderna's shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some changes to its strategy -- and a key goal.

Shares of Moderna (MRNA) fell for the second day in a row after the company said it would slash its research and development expenditures.

Moderna's cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of downgrades as analysts focused on longer timelines to launch some products and questioned when the company can return to profitability.